BR9913070A - Processos para modular a atividade do knfb, para identificar um composto ou compostos capazes de, direta ou indiretamente, modular a atividade do p105, para identificar um composto de referência para um produto farmacêutico utilizável no tratamento de doença que envolva ou use uma resposta inflamatória, composto identificável anticorpo, polipeptìdeo, e, processos para modular a atividade do p105 em uma célula, uso de um composto, para identificar um composto que regule uma resposta infamatória mediada pelo tpl-2, para identificar um composto que regule a transdução de sinal pelo tpl-2, para identificar um composto que module a interação de um polipeptìdeo do tpl-2 com um componente alvo de modulação do tpl-2, para tratar uma condição do sistema imune em um paciente em necessidade deste pela modulação da atividade do tpl-2, para tratar uma condição mediada pelo tpl-2 em um paciente, e para modular a regulagem do nfkb mediada pelo tpl-2 em um paciente em necessidade deste, processo para tratar a artrite reumatóide . - Google Patents
Processos para modular a atividade do knfb, para identificar um composto ou compostos capazes de, direta ou indiretamente, modular a atividade do p105, para identificar um composto de referência para um produto farmacêutico utilizável no tratamento de doença que envolva ou use uma resposta inflamatória, composto identificável anticorpo, polipeptìdeo, e, processos para modular a atividade do p105 em uma célula, uso de um composto, para identificar um composto que regule uma resposta infamatória mediada pelo tpl-2, para identificar um composto que regule a transdução de sinal pelo tpl-2, para identificar um composto que module a interação de um polipeptìdeo do tpl-2 com um componente alvo de modulação do tpl-2, para tratar uma condição do sistema imune em um paciente em necessidade deste pela modulação da atividade do tpl-2, para tratar uma condição mediada pelo tpl-2 em um paciente, e para modular a regulagem do nfkb mediada pelo tpl-2 em um paciente em necessidade deste, processo para tratar a artrite reumatóide .Info
- Publication number
- BR9913070A BR9913070A BR9913070-0A BR9913070A BR9913070A BR 9913070 A BR9913070 A BR 9913070A BR 9913070 A BR9913070 A BR 9913070A BR 9913070 A BR9913070 A BR 9913070A
- Authority
- BR
- Brazil
- Prior art keywords
- tpl
- compound
- identify
- activity
- modulate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 18
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 title abstract 16
- 230000000694 effects Effects 0.000 title abstract 8
- 230000001404 mediated effect Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 6
- 230000028709 inflammatory response Effects 0.000 title abstract 3
- 230000033228 biological regulation Effects 0.000 title abstract 2
- 210000000987 immune system Anatomy 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 title abstract 2
- 230000019491 signal transduction Effects 0.000 title abstract 2
- 101710128765 Enhancer of filamentation 1 Proteins 0.000 title 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 abstract 10
- 230000004913 activation Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9817930.2A GB9817930D0 (en) | 1998-08-18 | 1998-08-18 | Pathway |
| GBGB9827712.2A GB9827712D0 (en) | 1998-12-16 | 1998-12-16 | Pathway |
| PCT/US1999/018543 WO2000011191A2 (en) | 1998-08-18 | 1999-08-13 | Tpl-2/cot kinase and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9913070A true BR9913070A (pt) | 2001-05-08 |
Family
ID=26314223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9913070-0A BR9913070A (pt) | 1998-08-18 | 1999-08-13 | Processos para modular a atividade do knfb, para identificar um composto ou compostos capazes de, direta ou indiretamente, modular a atividade do p105, para identificar um composto de referência para um produto farmacêutico utilizável no tratamento de doença que envolva ou use uma resposta inflamatória, composto identificável anticorpo, polipeptìdeo, e, processos para modular a atividade do p105 em uma célula, uso de um composto, para identificar um composto que regule uma resposta infamatória mediada pelo tpl-2, para identificar um composto que regule a transdução de sinal pelo tpl-2, para identificar um composto que module a interação de um polipeptìdeo do tpl-2 com um componente alvo de modulação do tpl-2, para tratar uma condição do sistema imune em um paciente em necessidade deste pela modulação da atividade do tpl-2, para tratar uma condição mediada pelo tpl-2 em um paciente, e para modular a regulagem do nfkb mediada pelo tpl-2 em um paciente em necessidade deste, processo para tratar a artrite reumatóide . |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20020099169A1 (https=) |
| EP (1) | EP1105501A2 (https=) |
| JP (1) | JP4719831B2 (https=) |
| KR (1) | KR20010085407A (https=) |
| CN (1) | CN1323346A (https=) |
| AU (1) | AU767973B2 (https=) |
| BG (1) | BG105345A (https=) |
| BR (1) | BR9913070A (https=) |
| CA (1) | CA2339036A1 (https=) |
| CZ (1) | CZ2001625A3 (https=) |
| HK (1) | HK1041901A1 (https=) |
| HU (1) | HUP0103797A2 (https=) |
| ID (1) | ID28955A (https=) |
| IL (1) | IL141355A0 (https=) |
| MX (1) | MXPA01001747A (https=) |
| NO (1) | NO20010786L (https=) |
| NZ (1) | NZ510313A (https=) |
| PL (1) | PL347137A1 (https=) |
| RU (1) | RU2001107122A (https=) |
| SK (1) | SK2242001A3 (https=) |
| TR (2) | TR200100624T2 (https=) |
| WO (1) | WO2000011191A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6660906B1 (en) | 2000-03-08 | 2003-12-09 | Thomas Jefferson University | Tpl2 transgenic knockout mice |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| GB0402661D0 (en) * | 2004-02-06 | 2004-03-10 | Medical Res Council | TPL2 and its expression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| UA71889C2 (uk) * | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
-
1999
- 1999-08-13 HU HU0103797A patent/HUP0103797A2/hu unknown
- 1999-08-13 MX MXPA01001747A patent/MXPA01001747A/es unknown
- 1999-08-13 IL IL14135599A patent/IL141355A0/xx unknown
- 1999-08-13 JP JP2000566444A patent/JP4719831B2/ja not_active Expired - Fee Related
- 1999-08-13 PL PL99347137A patent/PL347137A1/xx not_active IP Right Cessation
- 1999-08-13 HK HK02103643.3A patent/HK1041901A1/zh unknown
- 1999-08-13 CN CN99812172A patent/CN1323346A/zh active Pending
- 1999-08-13 AU AU55633/99A patent/AU767973B2/en not_active Ceased
- 1999-08-13 WO PCT/US1999/018543 patent/WO2000011191A2/en not_active Ceased
- 1999-08-13 NZ NZ510313A patent/NZ510313A/en unknown
- 1999-08-13 CZ CZ2001625A patent/CZ2001625A3/cs unknown
- 1999-08-13 EP EP99942203A patent/EP1105501A2/en not_active Withdrawn
- 1999-08-13 SK SK224-2001A patent/SK2242001A3/sk unknown
- 1999-08-13 ID IDW20010645A patent/ID28955A/id unknown
- 1999-08-13 TR TR2001/00624T patent/TR200100624T2/xx unknown
- 1999-08-13 CA CA002339036A patent/CA2339036A1/en not_active Abandoned
- 1999-08-13 KR KR1020017002091A patent/KR20010085407A/ko not_active Abandoned
- 1999-08-13 RU RU2001107122/14A patent/RU2001107122A/ru not_active Application Discontinuation
- 1999-08-13 TR TR2001/03840T patent/TR200103840T2/xx unknown
- 1999-08-13 BR BR9913070-0A patent/BR9913070A/pt not_active IP Right Cessation
- 1999-08-13 US US09/374,579 patent/US20020099169A1/en not_active Abandoned
-
2001
- 2001-02-16 NO NO20010786A patent/NO20010786L/no not_active Application Discontinuation
- 2001-03-15 BG BG105345A patent/BG105345A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL347137A1 (en) | 2002-03-25 |
| KR20010085407A (ko) | 2001-09-07 |
| BG105345A (en) | 2001-12-31 |
| CN1323346A (zh) | 2001-11-21 |
| ID28955A (id) | 2001-07-19 |
| AU767973B2 (en) | 2003-11-27 |
| WO2000011191A3 (en) | 2000-06-08 |
| HUP0103797A2 (hu) | 2003-10-28 |
| HK1041901A1 (zh) | 2002-07-26 |
| CZ2001625A3 (cs) | 2002-02-13 |
| TR200103840T2 (tr) | 2002-06-21 |
| RU2001107122A (ru) | 2003-04-20 |
| JP2002531058A (ja) | 2002-09-24 |
| TR200100624T2 (tr) | 2001-08-21 |
| NZ510313A (en) | 2003-11-28 |
| EP1105501A2 (en) | 2001-06-13 |
| US20020099169A1 (en) | 2002-07-25 |
| WO2000011191A2 (en) | 2000-03-02 |
| MXPA01001747A (es) | 2003-06-06 |
| IL141355A0 (en) | 2002-03-10 |
| JP4719831B2 (ja) | 2011-07-06 |
| NO20010786D0 (no) | 2001-02-16 |
| SK2242001A3 (en) | 2001-10-08 |
| AU5563399A (en) | 2000-03-14 |
| NO20010786L (no) | 2001-04-17 |
| CA2339036A1 (en) | 2000-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gardell et al. | Multiple actions of systemic artemin in experimental neuropathy | |
| Sluka | Stimulation of deep somatic tissue with capsaicin produces long-lasting mechanical allodynia and heat hypoalgesia that depends on early activation of the cAMP pathway | |
| CHIN et al. | Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling | |
| Maegawa et al. | Thiazolidine Derivatives Ameliorate High Glucose-induced Insulin Resistance via the Normalization of Protein-tyrosine Phosphatase Activities (∗) | |
| Fréal et al. | Sodium channel endocytosis drives axon initial segment plasticity | |
| BR9710359A (pt) | Composto formulacao farmaceutica uso de um composto e processos para a preparacao de um composto e para tratamento de um individuo humano ou animal que esteja sofrendo de um disturbio mediado por atividade aberrante de tirosina cinase proteinica | |
| BRPI0411020A (pt) | perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição | |
| Touyz et al. | Modulation of vascular smooth muscle cell growth by magnesium—role of mitogen—activated protein kinases | |
| Conway | Bifunctional molecules beyond PROTACs | |
| BR0114344A (pt) | Retinóides para o tratamento de enfisema | |
| Atkins et al. | Regulation of myelin basic protein phosphorylation by mitogen‐activated protein kinase during increased action potential firing in the hippocampus | |
| PT862622E (pt) | Metodo de rastreio para compostos que interagem com proteina cinase rac | |
| BR9913070A (pt) | Processos para modular a atividade do knfb, para identificar um composto ou compostos capazes de, direta ou indiretamente, modular a atividade do p105, para identificar um composto de referência para um produto farmacêutico utilizável no tratamento de doença que envolva ou use uma resposta inflamatória, composto identificável anticorpo, polipeptìdeo, e, processos para modular a atividade do p105 em uma célula, uso de um composto, para identificar um composto que regule uma resposta infamatória mediada pelo tpl-2, para identificar um composto que regule a transdução de sinal pelo tpl-2, para identificar um composto que module a interação de um polipeptìdeo do tpl-2 com um componente alvo de modulação do tpl-2, para tratar uma condição do sistema imune em um paciente em necessidade deste pela modulação da atividade do tpl-2, para tratar uma condição mediada pelo tpl-2 em um paciente, e para modular a regulagem do nfkb mediada pelo tpl-2 em um paciente em necessidade deste, processo para tratar a artrite reumatóide . | |
| Machamer et al. | Antidotal treatment of botulism in rats by continuous infusion with 3, 4-diaminopyridine | |
| Kim et al. | PGE2 induces the gene expression of bone matrix metalloproteinase-1 in mouse osteoblasts by cAMP-PKA signaling pathway | |
| Antunes-Madeira et al. | Interaction of insecticides with the Ca2+-pump activity of sarcoplasmic reticulum | |
| FI902506A0 (fi) | Anordning foer att belaegga en materialbana som leds omkring en kontravals. | |
| ATE142499T1 (de) | Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren | |
| Beamish et al. | Sex differences in training-induced activity of the ubiquitin proteasome system in the dorsal hippocampus and medial prefrontal cortex of male and female mice | |
| ATE233812T1 (de) | Peptide mit pronociceptiveigenschaften | |
| NO933819D0 (no) | Analysesystemer for neurotrofinaktivitet | |
| ES2113909T3 (es) | Suero de control o calibracion, liquido y estable, para el diagnostico clinico. | |
| Steketee et al. | Injections of baclofen into the ventral medial prefrontal cortex block the initiation, but not the expression, of cocaine sensitization in rats | |
| Shteinikov et al. | Glutamate potentiates heterologously expressed homomeric acid‐sensing ion channel 1a | |
| Fleming et al. | Regulation of the cAMP signal transduction pathway by protein kinase C in rat submandibular cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 9A., 10A. E 11A. ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010. |